Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
![Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Structure](CAS/20210305/GIF/251442-94-1.gif)
- CAS No.
- 251442-94-1
- Chemical Name:
- Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
- Synonyms
- Enflicoxib;E6087;E-6087;E 6087;Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
- CBNumber:
- CB89280472
- Molecular Formula:
- C16H12F5N3O2S
- Molecular Weight:
- 405.34
- MDL Number:
- MOL File:
- 251442-94-1.mol
- MSDS File:
- SDS
Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Properties
| Boiling point | 461.4±55.0 °C(Predicted) |
|---|---|
| Density | 1.57±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO : 100 mg/mL (246.71 mM; ultrasonic and warming and heat to 60°C) |
| pka | 10.39±0.10(Predicted) |
| form | Solid |
| color | White to off-white |
| SMILES | O=S(N)(C1=CC=C(N2N=C(C(F)(F)F)CC2C3=CC=C(C=C3F)F)C=C1)=O |
| FDA UNII | VM9PYQ1MQG |
| UNSPSC Code | 12352200 |
| NACRES | NA.28 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS08,GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H373 |
| Precautionary statements | P260-P264-P270-P301+P312-P314-P501 |
| target organs | Gastrointestinal tract |
| WGK Germany | WGK 3 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral STOT RE 2 |
Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0015483 | Enflicoxib 99.88% | 251442-94-1 | 5mg | $97 | 2026-06-04 | Buy |
| ChemScene | CS-0015483 | Enflicoxib 99.88% | 251442-94-1 | 10mg | $166 | 2026-06-04 | Buy |
| ChemScene | CS-0015483 | Enflicoxib 99.88% | 251442-94-1 | 25mg | $348 | 2026-06-04 | Buy |
| ChemScene | CS-0015483 | Enflicoxib 99.88% | 251442-94-1 | 50mg | $590 | 2026-06-04 | Buy |
| ChemScene | CS-0015483 | Enflicoxib 99.88% | 251442-94-1 | 100mg | $1003 | 2026-06-04 | Buy |
Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Chemical Properties,Uses,Production
Uses
Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2 (COX-2).Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models[1].
Biological Activity
Orally available, potent and selective cyclooxygenase 2 (COX-2) inhibitor
in vivo
E-6132, one of Enflicoxib (E-6087) metabolites, also inhibits COX-2.After single oral administration of 5 mg/kg of E-6087 to rats, plasma concentrations of Enflicoxib at peak time are higher than those of E-6132, suggesting that activity is mainly due to Enflicoxib[1].
Enflicoxib (E-6087) is characterized by a long elimination half-life (20-35 h), a low plasma clearance (0.10-0.22 L/h/kg) and a relatively large volume of distribution (2-6 L/kg) in rats and dogs after single oral and intravenous doses. Enflicoxib and E-6132 (a pharmacologically active metabolite) show different pharmacokinetics. The higher percentage of Enflicoxib at early times suggests that Enflicoxib is the main compound responsible for in vivo activity, although E-6132 would contribute to the activity at later times[2].
| Animal Model: | Male and female Wistar rats (250 g)[1] |
| Dosage: | 5 mg/kg |
| Administration: | Administered by gastric gavage (10 mL/kg); a single oral dose |
| Result: | Plasma concentrations of E-6087 at peak time are higher than those of E-6132. |
IC 50
COX-2
References
[1] Carlos Pérez-Maseda,et al. Determination of enantiomeric purity of a novel COX-2 anti-inflammatory drug by capillary electrophoresis using single and dual cyclodextrin systems. Electrophoresis.2003 May;24(9):1416-21. DOI:10.1002/elps.200390182
[2] R F Reinoso,et al. Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. Biopharm Drug Dispos.2001 Sep;22(6):231-42. DOI:10.1002/bdd.258
Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Preparation Products And Raw materials
Raw materials
Preparation Products
Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Haozhixiang Biotechnology Co., Ltd | 526763801 13301653310 | 526763801@qq.com | China | 7580 | 55 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Shanghai?Medlife?Pharm-Tech?Co.,?Ltd | 4000862158 18117107507 | vip@med-life.cn | China | 4999 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Shanghai Amole Biotechnology Co., Ltd. | 13370042665 18916960931 | 2596183085@qq.com | China | 17234 | 58 |
| TargetMol Chemicals Inc. | 13564774135 | marketing@targetmol.com | United States | 19950 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 50089 | 58 |
View Lastest Price from Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-09 | Enflicoxib
251442-94-1
|
$160.00 | 99.27% | 10g | TargetMol Chemicals Inc. |
-
- Enflicoxib
251442-94-1
- $160.00
- 99.27%
- TargetMol Chemicals Inc.
